Denali's Alzheimer's drug faces setback at the FDA after agency slaps clinical hold on human trial start

Kyle Blankenship

Denali Therapeutics was once a Cinderella story in neurology with high expectations on a platform it thinks could offer much greater brain penetration. Since then …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Denali's Alzheimer's drug faces setback at the FDA after agency slaps clinical hold on human trial start

Kyle Blankenship

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

De­nal­i's Alzheimer's drug faces set­back at the FDA af­ter agency slaps clin­i­cal hold on hu­man tri­al start

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Denali's Alzheimer's drug faces setback at the FDA after agency slaps clinical hold on human trial start